Translational Development Acquisition Corp. (TDAC) EBITDA (2024 - 2026)

Translational Development Acquisition (TDAC) has reported EBITDA for 3 consecutive years, with -$661050.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 198.95% year-over-year to -$661050.0; the trailing twelve-month figure through Jun 2026 stood at -$1.3 million (down 72.72% YoY), and the FY2025 full-year result was -$944538.0, down 381.03% from the prior year.
• EBITDA eased to -$661050.0 in Q2 2026 per TDAC's latest filing, from -$281161.0 in the prior quarter.
• Across five years, EBITDA topped out at -$61283.0 in Q3 2024 and bottomed at -$661050.0 in Q2 2026.
• Historically, EBITDA has averaged -$260177.8 across 3 years, with a median of -$217392.5 in 2025.
• The sharpest annual moves came in 2025 and 2026: EBITDA tumbled 248.64% in 2025, then increased 19.07% in 2026.
• Over 3 years, EBITDA stood at -$133390.0 in 2024, then slipped by 21.71% to -$162345.0 in 2025, then sank by 307.19% to -$661050.0 in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$661050.0, -$281161.0, and -$162345.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.